Entries by Admin

Trethera Corporation, a biopharmaceutical company committed to developing novel drugs targeting cellular nucleotide metabolism for the treatment of cancer, will attend the 2018 BIO CEO & Investor Conference on February 12-13, 2018 in New York City.

Los Angeles, CA / February 5, 2018 – Trethera Corporation, a biopharmaceutical company committed to developing novel drugs targeting cellular nucleotide metabolism for the treatment of cancer, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for TRE-515, a novel, first-in-class inhibitor of deoxycytidine kinase for the […]

November 27, 2017 – Trethera Corporation will be attending the American Society of Hematology (ASH) Annual Meeting in Atlanta from December 9-12, 2017. Trethera is preparing for initiation of a Phase 1 clinical trial in myelodysplastic syndrome (MDS) for its small molecule, deoxycytidine kinase inhibitor, TRE-515.

September 7, 2017 – Trethera, a biotechnology company developing innovative small molecule inhibitors of cancer nucleotide metabolism, will be attending the BioPharma America conference in Boston, MA, September 26-27, 2017.

September 7, 2017 – Trethera will be attending the Society of Hematologic Oncology’s Annual Meeting, September 13-15, 2017, in Houston, Texas. For more information on Trethera’s attendance, please contact info@trethera.com

Abstract Leukemia cells rely on two nucleotide biosynthetic pathways, de novo and salvage, to produce dNTPs for DNA replication. Here, using metabolomic, proteomic, and phosphoproteomic approaches, we show that inhibition of the replication stress sensing kinase ataxia telangiectasia and Rad3-related protein (ATR) reduces the output of both de novo and salvage pathways by regulating the […]